Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy:: Clinical implications

被引:26
作者
Paya, Eduardo [1 ]
Marin, Francisco [1 ,3 ]
Gonzalez, Josefa [3 ]
Ramon Gimeno, Juan [3 ]
Feliu, Eloisa [2 ]
Romero, Antonio [3 ]
Ruiz-Espejo, Francisco [4 ]
Roldan, Vanessa [5 ]
Climent, Vicente [1 ]
de la Morena, Gonzalo [3 ]
Valdes, Mariano [3 ]
机构
[1] Hosp Gen Univ, Dept Cardiol, Alicante, Spain
[2] Hosp Gen Univ, Magnet Resonance Unit, Alicante, Spain
[3] Hosp Virgen Arrixaca, Dept Cardiol, Murcia, Spain
[4] Hosp Virgen Arrixaca, Dept Clin Anal, Murcia, Spain
[5] Hosp Morales Meseguer, Dept Hematol & Med Oncol, Murcia, Spain
关键词
hypertrophic cardiomyopathy; gadolinium hyperenhancement; cardiac magnetic resonance; NTproBNP;
D O I
10.1016/j.cardfail.2008.02.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hypertrophic cardiomyopathy (HCM) shows increased myocardial collagen and disarray. Late gadolinium enhancement in cardiovascular magnetic resonance (CMR) is observed in regions of increased myocardial collagen. The extent of late gadolinium enhancement has been associated with higher prevalence of risk factors of sudden death. The aim of the present study was to describe the clinical characteristics and the presence of risk factors for sudden death in a series of patients from 2 referral centers for HCM in relation to late gadolinium enhancement in CMR. Methods and Results: A total of 120 patients (47 +/- 16 years) were included. All patients fulfilled conventional criteria for HCM. A complete history and clinical examination were performed. Risk factors for sudden death were evaluated. A blinded CMR was performed with late gadolinium enhancement in the left ventricular short-axis orientation. NT pro B-type natriuretic protein (BNP) and C-reactive protein were determined in serum samples. A total of 83 patients (69%) showed late gadolinium enhancement. These patients had higher maximal left ventricular wall thickness (22 +/- 5 versus 17 +/- 3 mm, P < .001), showed more frequently obstruction (42% versus 16%, P = .006), nonsustained ventricular tachycardia (38% versus 8%, P = .001), worse exercise capacity (8 +/- 4 versus 10 4 METs, P = .003) and increased levels of NT BNP (656 [300-1948] versus 290 [122-948] pg/mL, P = .020). On multivariate analysis, maximal left ventricular wall thickness (P < .001) and nonsustained ventricular tachycardia (P = .011) remained associated with gadolinium-enhanced imaging. Number of risk factors for sudden death was associated with late gadolinium enhancement (OR 2.18, 95%CI 1.45-3.20, P < .001). Conclusions: Late gadolinium enhancement in CMR is a common finding in HCM. Increased maximal left ventricular wall thickness and nonsustained ventricular tachycardia are associated with late gadolinium enhancement. Associations with risk factors for sudden death and functional status are observed.
引用
收藏
页码:414 / 419
页数:6
相关论文
共 37 条
[11]   B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts -: Fibrosis, myofibroblast conversion, proliferation, and inflammation [J].
Kapoun, AM ;
Liang, FQ ;
O'Young, G ;
Damm, DL ;
Quon, D ;
White, RT ;
Munson, K ;
Lam, A ;
Schreiner, GF ;
Protter, AA .
CIRCULATION RESEARCH, 2004, 94 (04) :453-461
[12]   Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function [J].
Kim, RJ ;
Fieno, DS ;
Parrish, TB ;
Harris, K ;
Chen, EL ;
Simonetti, O ;
Bundy, J ;
Finn, JP ;
Klocke, FJ ;
Judd, RM .
CIRCULATION, 1999, 100 (19) :1992-2002
[13]   Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy [J].
Maron, BJ ;
Tholakanahalli, VN ;
Zenovich, AG ;
Casey, SA ;
Duprez, D ;
Aeppli, DM ;
Cohn, JN .
CIRCULATION, 2004, 109 (08) :984-989
[14]   Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy [J].
Maron, MS ;
Olivotto, I ;
Betocchi, S ;
Casey, SA ;
Lesser, JR ;
Losi, MA ;
Cecchi, F ;
Maron, BJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (04) :295-303
[15]   Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy [J].
Matoh, Fumitaka ;
Satoh, Hiroshi ;
Shiraki, Katsunori ;
Saitoh, Takeji ;
Urushida, Tsuyoshi ;
Katoh, Hideki ;
Takehara, Yasuo ;
Sakahara, Harumi ;
Hayashi, Hideharu .
JOURNAL OF CARDIAC FAILURE, 2007, 13 (05) :372-379
[16]   Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure [J].
May, Heidi T. ;
Muhlestein, Joseph B. ;
Carlquist, John F. ;
Horne, Benjamin D. ;
Bair, Tami L. ;
Campbell, Beverly A. ;
Kfoury, Abdallah G. ;
Lyon, Joseph L. ;
Kim, Han ;
Renlund, Dale G. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (05) :653-658
[17]   Experience from clinical genetics in hypertrophic cardiomyopathy: Proposal for new diagnostic criteria in adult members of affected families [J].
McKenna, WJ ;
Spirito, P ;
Desnos, M ;
Dubourg, O ;
Komajda, M .
HEART, 1997, 77 (02) :130-132
[18]   Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients [J].
Monserrat, L ;
Elliott, PM ;
Gimeno, JR ;
Sharma, S ;
Penas-Lado, M ;
McKenna, WJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (05) :873-879
[19]   What is late gadolinium enhancement in hypertrophic cardiomyopathy? [J].
Moon, James C. .
REVISTA ESPANOLA DE CARDIOLOGIA, 2007, 60 (01) :1-4
[20]   The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease [J].
Moon, James C. ;
Sheppard, Mary ;
Reed, Emma ;
Lee, Phillip ;
Elliott, Perry M. ;
Pennell, Dudley J. .
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2006, 8 (03) :479-482